SEARCH

SEARCH BY CITATION

Additional Supporting Information may be found in the online version of this article.

FilenameFormatSizeDescription
hep26641-sup-0001-suppfig1.tif1234KSupplementary Fig. A. Patient disposition.
hep26641-sup-0002-supptablesA-C.doc58K

Supplementary Table A. Rates of Study Drug Discontinuation

Supplementary Table B. Rates of Viral Breakthrough and Relapse, Overall and at Selected Time Points

Supplementary Table C. Sustained Virologic Response 12 Weeks and 24 Weeks after Planned End of Treatment for the Simeprevir 150 mg and 75 mg Dose Groups and Placebo by IL28B Genotype

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.